Mineralys TherapeuticsvsMerck & Company

MLYS and MRK stock compared: price, dividend, valuation and results, from SEC filings.

MLYS

Mineralys Therapeutics, Inc.

$13.66

Value $1.2B

-3.53%
MLYS's page

MRK

Merck & Company, Inc.

$133.72

Value $331B

+0.69%
MRK's page

Mineralys Therapeutics (MLYS) has a market value of $1.2B and Merck & Company (MRK) $331B. Over the last year, with dividends, MLYS moved -67.6% and MRK +44.8%. Dividend yield: MLYS none, MRK 2.54%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    MLYS$1.2B

    MRK$331B

    MRK is 273 times MLYS

  • Revenue, 12 months

    MLYS–

    MRK$67.4B

  • Net income, 12 months

    MLYS-$370M

    MRK$2.5B

  • Operating margin

    MLYS–

    MRK–

  • ROIC

    MLYS-20.8%

    MRK3.9%

    24.7 points apart

  • P/E

    MLYS–

    MRK134.8

  • Dividend yield

    MLYS0.0%

    MRK2.5%

    2.5 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

MLYS+112.4%

MRK+42.7%

200400600202420252026
Returns by period
PeriodMLYSWith dividendsMRKWith dividends
1 year since November 19, 2025-67.6%Price -67.6%+44.8%Price +40.7%
3 years since November 20, 2023+112.4%+28.6% a yearPrice +112.4%+42.7%+12.6% a yearPrice +30.2%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

MLYSMineralys TherapeuticsMRKMerck & Company

Valuation

MLYSMRK
Valuation
Price$13.66$133.72
Market value$1.2B$331B
Enterprise value (EV)$585M$375B
P/E–134.8
P/E, 5-year median–14.8
P/B2.47.4
EV/EBIT–78.7
Free cash flow yield–4.5%

Results and growth

MLYSMRK
Results and growth
Revenue, 12 months–$67.4B
Net income, 12 months-$370M$2.5B
Free cash flow, 12 months-$153M$14.7B
Earnings per share, 12 months-$4.31$0.98
Revenue growth, year on year–1.3%
Revenue growth a year, past–+9.4%over 5 years
EPS growth a year, past–+21.2%over 5 years

Margins and returns on capital

MLYSMRK
Margins and returns on capital
Gross margin–71.8%
Operating margin––
Net margin–3.6%
ROIC-20.8%3.9%
ROE-63.4%5.2%

Balance sheet

MLYSMRK
Balance sheet
Cash$625M$9.7B
Total debt$100.0K$53.8B
Net debt / EBITDA–5.7
Interest cover–2.4×

Dividends and buybacks

MLYSMRK
Dividends and buybacks
Dividend yield–2.5%
Dividend per share, 12 months–$3.40
Dividend growth a year, past–+5.8%over 5 years
Buyback yield–1.5%
Shareholder yield–4.1%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: MLYS or MRK

Didn't find what you were looking for?

Ask us
Which is bigger, Mineralys Therapeutics or Merck & Company?

By market value, Merck & Company ($331B) is about 273.3 times Mineralys Therapeutics ($1.2B), at today's prices.

How did MLYS and MRK stock do over the last 3 years?

Since November 20, 2023, MLYS's price moved +112.4% and MRK's +30.2%. With dividends: MLYS +112.4% (+28.6% a year), MRK +42.7% (+12.6% a year). Past returns do not predict future ones.

Which pays the higher dividend, MLYS or MRK?

The dividend yield at today's price is none for Mineralys Therapeutics and 2.54% for Merck & Company. Over the last twelve months they paid – and $3.40 per share.

Which is the better investment, Mineralys Therapeutics or Merck & Company?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.